Johnson & Johnson COVID-19 vaccine produces strong immune response.
According to interim results published on Friday, a single dose of Johnson & Johnson’s experimental COVID-19 vaccine produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial.
The result furtherly revealed that the vaccine, called Ad26.COV2.S, was equally well-tolerated at two different doses, the results showed. A single shot, versus a rival two-dose approach being tested by Moderna Inc and Pfizer Inc , could simplify distribution of the vaccine.
However, it is unclear whether elderly people, one of the populations most at risk from the virus, will be protected to the same degree as younger people with the J&J vaccine.
The trial was done by U.S. Government in close to 1,000 healthy adults, began after the J&J vaccine was found in July to offer strong protection in a single dose to monkeys.
As per the recent report, J&J on Wednesday kicked off a final 60,000-person trial, which could pave the way for an application for regulatory approval. The company said it expects results of that so-called Phase 3 trial by the end of the year or early next year.